ClinicalTrials.gg
CompletedNCT00152477Updated Apr 12, 2022Results posted

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

A Phase 2 interventional study of Carboplatin and Paclitaxel in Carcinoma and Non-Squamous Non-Small-Cell Lung Cancer, sponsored by UCB Pharma. Completed at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 22 studies testing carboplatin in Carcinoma — 1 open to participants now, 5 under way, 3 of them phase 3. Carboplatin · Carcinoma.

Enrollment
8th of 22
165 · median 41
Started
2005
the only one that year
Phase 2
15 of 22
1 open now
Registered
2nd of 22
by date

Among the 22 studies testing carboplatin in Carcinoma, this one is the 8th largest by enrollment, is the only one that started in 2005, is one of 15 in phase 2, and was the 2nd registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

1 of the 22 studies testing carboplatin in Carcinoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing carboplatin in Carcinoma, or all of them as a file.
02

Study summary

A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour effects (part 2), of CDP791 combined with carboplatin and paclitaxel.

Read the detailed description

This is a two part study to investigate the safety and anti-tumour effects of standard chemotherapy, plus an investigational drug (CDP791), in patients with advanced non small cell lung cancer.

In part one, patients receive carboplatin and paclitaxel chemotherapy together with one of 2 doses of CDP791. The main aim of this part is to investigate safety and tolerability of carboplatin/paclitaxel plus CDP791.

If part one confirms that the combination of drugs is safe and well tolerated, 156 patients will enter part 2. They will be randomized to receive either carboplatin/paclitaxel (C/P) alone, or C/P plus one of 2 doses of CDP791. The main aim of this part of the study is to compare the anti-tumor effects of CDP791 plus C/T with those of C/T alone. Participants will receive up to six cycles of chemotherapy with or without CDP791. Those whose disease stabilizes, or responds, will be eligible to continue to receive CDP791. Participants in the C/T alone arm whose disease progresses will be eligible to receive CDP791 monotherapy.

Participants will be followed up longterm, so that survival can be measured.

03

Conditions studied

  • Carcinoma
  • Non-Squamous Non-Small-Cell Lung Cancer

Keywords

  • Non-small-cell-lung cancer
  • carboplatin
  • paclitaxel
  • VEGF
  • monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria:

  • Male and female subjects with Stage IIIb (with malignant pleural effusion or if no pleural effusion is present subjects who are not candidates for combined modality therapy), Stage IV, or recurrent non-squamous, non-small-cell lung carcinoma.
  • The subject must be aged 18 years or above.
  • The subject must have performance status of 0 or 1 and a of at least three months.
  • Subjects will have .
  • The subject must be able to understand the information provided to them and to give written .
  • Female subjects must be either , surgically sterilized, or using a method of judged reliable by the Investigator.
  • Male subjects must be using a method of contraception judged reliable by the Investigator.

Exclusion Criteria:

  • Subjects with squamous cell lung carcinoma.
  • Subjects with lung lesions located centrally in the chest that involve major blood vessels.
  • Concurrent active other than nonmelanoma skin cancer or carcinoma in situ of the cervix. Subjects with previous malignancies are eligible provided that they have been disease free for five years or more.
  • Presence of additional major chronic disease such as hepatic or renal dysfunction, cardiac dysfunction, peripheral vascular disease, evidence of a myocardial infarction within six months of Screening visit, tuberculosis or epilepsy.
  • Subjects known to be infected with or C virus or 1 or 2.
  • Any evidence of serious active infection (ie requiring an iv antibiotic or antiviral agent).

Exclusion Criteria:

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Carboplatin/Paclitaxel

    Carboplatin and paclitaxel alone.

    Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    Carboplatin/Paclitaxel/CDP791 10mg

    Carboplatin and paclitaxel plus CDP791 10mg/kg

    Drug: Carboplatin · Drug: Paclitaxel · Drug: CDP791 10mg/kg · Drug: CDP791 20mg/kg

  • Experimental
    Carboplatin/Paclitaxel/CDP791 20mg

    Carboplatin and paclitaxel plus CDP791 20mg/kg

    Drug: Carboplatin · Drug: Paclitaxel · Drug: CDP791 10mg/kg · Drug: CDP791 20mg/kg

Interventions

  • 10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle. Each cycle to be repeated every three weeks for a maximum of six cycles.

    Also known as: CBDCA, Paraplatin, JM-8, NSC 241240

  • 6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.

    Also known as: Taxol, NSC #673089

  • DrugCDP791 10mg/kg

    CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.

  • DrugCDP791 20mg/kg

    CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.

06

What researchers measure

Primary outcomes

  1. Tumor Response Rate (RR)

    Participants are evaluated for response using Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse P et al; 2000). The tumor response rate is calculated as the total number of subjects whose best overall response is a complete response (CR)= disappearance of all target lesions; or a partial response (PR) = \>=30 % decrease in the sum of the longest diameter of target lesions, divided by the number of randomized subjects (RS): (CR + PR) / RS.

    Time frame: 24 weeks

Secondary outcomes

  1. Progression Free Survival (PFS)

    Progression free survival (PFS) is defined as time from date of randomization until the date progressive disease (PD) is first recorded or until death, whichever is first.

    Time frame: Up to 57 weeks

  2. Time to Treatment Failure

    Time to treatment failure (TTF) is defined as the time from date of randomization until the date of progression, death or, for subjects who discontinued treatment for toxicity reason, their last dosing date, whichever occurs first.

    Time frame: Up to 57 weeks

  3. Overall Survival

    Overall survival is defined as the time from date of randomization until the date of death.

    Time frame: Up to 57 weeks

  4. Duration of Overall Response

    The duration of overall response is measured from the time measurement criteria are first met for complete response (CR) or partial response (PR), whichever is recorded first, until the first date of documented progressive disease or death.

    Time frame: Up to 57 weeks

  5. Time to Response

    Time to response is defined as the time from the first dose of study therapy until measurement criteria are first met for complete response or partial response (whichever is recorded first).

    Time frame: Week 24

07

Results

Posted Apr 12, 2022

Participant flow

The study started to enroll patients in August 2005 and concluded in June 2009. Across Part I (dose escalation) and Part II (Open Label randomized) of the study, 165 subjects were analyzed. Part II was opened for 156 response-evaluable subjects.

Chemotherapy Period
Participant flow — Chemotherapy Period
MilestoneCarboplatin/PaclitaxelCarboplatin/Paclitaxel/CDP791 10mgCarboplatin/Paclitaxel/CDP791 20mg
Started505659
Part ii505353
Completed223439
Not completed282220
Withdrew: Adverse event945
Withdrew: Death133
Withdrew: Lack of efficacy456
Withdrew: Lost to follow-up101
Withdrew: Protocol violation110
Withdrew: Withdrawal by subject510
Withdrew: Progression of disease684
Withdrew: Investigator decision001
Withdrew: Patient condition worsened100
Monotherapy Period
Participant flow — Monotherapy Period
MilestoneCarboplatin/PaclitaxelCarboplatin/Paclitaxel/CDP791 10mgCarboplatin/Paclitaxel/CDP791 20mg
Started152934
Part ii132629
Completed000
Not completed152934
Withdrew: Adverse event105
Withdrew: Death201
Withdrew: Lack of efficacy71610
Withdrew: Protocol violation010
Withdrew: Withdrawal by subject004
Withdrew: Progression of disease51112
Withdrew: Patient decision011
Withdrew: Study personel decision001

Outcome measures

PrimaryTumor Response Rate (RR)

Participants are evaluated for response using Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse P et al; 2000). The tumor response rate is calculated as the total number of subjects whose best overall response is a complete response (CR)= disappearance of all target lesions; or a partial response (PR) = \>=30 % decrease in the sum of the longest diameter of target lesions, divided by the number of randomized subjects (RS): (CR + PR) / RS.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Tumor Response Rate (RR)
percentage of participantsCarboplatin/Paclitaxel (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS)Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS)
Complete responder0000
Partial responder2026.422.630.2
Statistical analysis
  • Carboplatin/Paclitaxel (Randomized Part II SjS) vs Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS) · Cochran-Mantel-Haenszel · p = =0.384 (Two-sided Chi-square test. Fisher's Exact test presented when number of responders in a treatment group is \<5.) · Difference of response rate: 6.4 · 95% CI -7.7 to 20.5
  • Carboplatin/Paclitaxel (Randomized Part II SjS) vs Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS) · Cochran-Mantel-Haenszel · p = =0.409 (CMH test stratified by country and disease stage (3 levels: Stage IIIb without malignant pleural effusion versus Stage IIIb with malignant pleural effusion or Stage IV or recurrent).) · Difference of response rate: 6.4 · 95% CI -7.7 to 20.5
  • Carboplatin/Paclitaxel (Randomized Part II SjS) vs Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS) · Chi-squared · p = =0.744 (Two-sided Chi-square test. Fisher's Exact test presented when number of responders in a treatment group is \< 5.) · Difference of response rate: 2.6 · 95% CI -13.5 to 18.8
  • Carboplatin/Paclitaxel (Randomized Part II SjS) vs Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS) · Cochran-Mantel-Haenszel · p = =0.783 (CMH test stratified by country and disease stage (3 levels: Stage IIIb without malignant pleural effusion versus Stage IIIb with malignant pleural effusion or Stage IV or recurrent).) · Difference of response rate: 2.6 · 95% CI -13.5 to 18.8
  • Carboplatin/Paclitaxel (Randomized Part II SjS) vs Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS) · Chi-squared · p = =0.234 (Two-sided Chi-square test. Fisher's Exact test presented when number of responders in a treatment group is \< 5.) · Difference of response rate: 10.2 · 95% CI -6.8 to 27.2
  • Carboplatin/Paclitaxel (Randomized Part II SjS) vs Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS) · Cochran-Mantel-Haenszel · p = =0.228 (CMH test stratified by country and disease stage (3 levels: Stage IIIb without malignant pleural effusion versus Stage IIIb with malignant pleural effusion or Stage IV or recurrent).) · Difference of response rate: 10.2 · 95% CI -6.8 to 27.2
SecondaryProgression Free Survival (PFS)

Progression free survival (PFS) is defined as time from date of randomization until the date progressive disease (PD) is first recorded or until death, whichever is first.

Time frame:
Up to 57 weeks
Reported as:
Median · weeks
Progression Free Survival (PFS)
weeksCarboplatin/Paclitaxel (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS)Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS)
Progression Free Survival (PFS)24.14 (20.29 to 29.29)26.86 (24.43 to 30.14)26.86 (21.14 to 30.71)25.43 (24.29 to 30.43)
SecondaryTime to Treatment Failure

Time to treatment failure (TTF) is defined as the time from date of randomization until the date of progression, death or, for subjects who discontinued treatment for toxicity reason, their last dosing date, whichever occurs first.

Time frame:
Up to 57 weeks
Reported as:
Median · weeks
Time to Treatment Failure
weeksCarboplatin/Paclitaxel (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS)Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS)
Time to Treatment Failure13.21 (6.86 to 20.29)21.71 (18.14 to 24.71)18.43 (12.14 to 24.71)24.29 (18.14 to 27.00)
SecondaryOverall Survival

Overall survival is defined as the time from date of randomization until the date of death.

Time frame:
Up to 57 weeks
Reported as:
Median · weeks
Overall Survival
weeksCarboplatin/Paclitaxel (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS)Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS)
Overall Survival36.14 (27.14 to 64.14)47.14 (40.43 to 56.00)46.57 (38.57 to 59.86)47.57 (31.29 to 75.00)
SecondaryDuration of Overall Response

The duration of overall response is measured from the time measurement criteria are first met for complete response (CR) or partial response (PR), whichever is recorded first, until the first date of documented progressive disease or death.

Time frame:
Up to 57 weeks
Reported as:
Median · weeks
Duration of Overall Response
weeksCarboplatin/Paclitaxel (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS)Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS)
Duration of Overall Response21.14 (19.14 to NA)21.14 (16.86 to 22.43)21.14 (19.29 to NA)18.00 (16.71 to 22.43)
SecondaryTime to Response

Time to response is defined as the time from the first dose of study therapy until measurement criteria are first met for complete response or partial response (whichever is recorded first).

Time frame:
Week 24
Reported as:
Median · weeks
Time to Response
weeksCarboplatin/Paclitaxel (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS)Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS)Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS)
Time to Response8.57 (8.14 to 17.43)9.14 (8.36 to 16.64)11.86 (8.86 to 16.64)9.00 (8.21 to 15.29)

Adverse events

Collected over Adverse events were collected from Visit 1 until Safety Follow-Up Visit (for up to 57 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carboplatin/Paclitaxel (SS)30/50 (60%)18/50 (36%)44/50 (88%)
Carboplatin/Paclitaxel/CDP791 (SS)72/115 (62.6%)36/115 (31.3%)110/115 (95.7%)
Carboplatin/Paclitaxel/CDP791 10mg (SS)39/56 (69.6%)18/56 (32.1%)54/56 (96.4%)
Carboplatin/Paclitaxel/CDP791 20mg (SS)33/59 (55.9%)18/59 (30.5%)56/56 (100%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventCarboplatin/Paclitaxel (SS)Carboplatin/Paclitaxel/CDP791 (SS)Carboplatin/Paclitaxel/CDP791 10mg (SS)Carboplatin/Paclitaxel/CDP791 20mg (SS)
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/502/1150/562/59
AnaemiaBlood and lymphatic system disorders4/506/1152/564/59
ThrombocytopeniaBlood and lymphatic system disorders0/505/1152/563/59
Respiratory failureRespiratory, thoracic and mediastinal disorders1/503/1150/563/59
Oedema peripheralGeneral disorders2/500/1150/560/59
DyspnoeaRespiratory, thoracic and mediastinal disorders2/500/1150/560/59
Weight decreasedInvestigations1/503/1152/561/59
FatigueGeneral disorders1/502/1150/562/59
Cardiac failureCardiac disorders1/501/1150/561/59
Cardiopulmonary failureCardiac disorders1/501/1151/560/59
Most frequent other events
Showing 10 of 46
Most frequent other events
EventCarboplatin/Paclitaxel (SS)Carboplatin/Paclitaxel/CDP791 (SS)Carboplatin/Paclitaxel/CDP791 10mg (SS)Carboplatin/Paclitaxel/CDP791 20mg (SS)
NeutropeniaBlood and lymphatic system disorders15/5042/11519/5623/56
AlopeciaSkin and subcutaneous tissue disorders18/5038/11519/5619/56
AnaemiaBlood and lymphatic system disorders17/5035/11517/5618/56
LeukopeniaBlood and lymphatic system disorders4/5023/11514/569/56
FatigueGeneral disorders10/5016/1159/567/56
ThrombocytopeniaBlood and lymphatic system disorders8/5019/1158/5611/56
NauseaGastrointestinal disorders7/5016/1156/5610/56
AnorexiaMetabolism and nutrition disorders6/5018/1158/5610/56
ArthralgiaMusculoskeletal and connective tissue disorders2/5014/1154/5610/56
Bone painMusculoskeletal and connective tissue disorders1/5015/1156/569/56

Baseline characteristics

Baseline Characteristics refer to all response-evaluable Part II subjects.

Age, Categorical
Age, Categorical(Participants)Carboplatin/PaclitaxelCarboplatin/Paclitaxel/CDP791 10mgCarboplatin/Paclitaxel/CDP791 20mgTotal Title
<=18 years0000
Between 18 and 65 years303540105
>=65 years20181351
Age, Continuous
Age, Continuous(years)Carboplatin/PaclitaxelCarboplatin/Paclitaxel/CDP791 10mgCarboplatin/Paclitaxel/CDP791 20mgTotal Title
Mean61.58 ± 10.6960.70 ± 10.0158.25 ± 9.3860.15 ± 10.06
Sex: Female, Male
Sex: Female, Male(Participants)Carboplatin/PaclitaxelCarboplatin/Paclitaxel/CDP791 10mgCarboplatin/Paclitaxel/CDP791 20mgTotal Title
Female20212970
Male30322486
08

Study locations

22 sites
  • Budapest, Hungary
  • Deszk, Hungary
  • Matrahaza, Hungary
  • Nyiregyhaza, Hungary
  • Pecs, Hungary
  • Krakow, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Olsztyn, Poland
  • Otwock, Poland
  • Poznan, Poland
  • Radom, Poland
  • Szczecin, Poland
  • Torun, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Zabrze, Poland
  • Kazan, Russian Federation
  • Moscow, Russian Federation
  • Moskow, Russian Federation
  • Saint Petersburg, Russian Federation
  • Samara, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2005 to primary completion in Jun 2009, 46 months.

Results were first posted in Apr 2022, 12 years 9 months after primary completion.

Of 82 phase 2 interventional studies under Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 88. This study's 46 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 9, 2005
StartActual
Aug 15, 2005
Primary completionActual
Jun 25, 2009
CompletionActual
Jun 25, 2009
Results first posted
Apr 12, 2022
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00152477
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 9, 2005
Start date
Aug 15, 2005
Primary completion
Jun 25, 2009
Completion
Jun 25, 2009
Results posted
Apr 12, 2022
Last update
Apr 12, 2022

Study contacts

UCB Cares
study director · UCB (+1 844 599 2273)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Paclitaxel

Start the discussion